Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150–200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maroun J: Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. Semin Oncol 15:17–21, 1988

    Google Scholar 

  2. Maroun JA, Robert F, Natale RB, Hait WN, Bunn PA, Meyer M, Kowal C: Pilot study of trimetrexate (CI-898) administered in combination with cisplatin or etoposide to patients with nonsmall cell lung cancer. Proc Am Soc Clin Oncol 9:243, 1990 (abstr)

    Google Scholar 

  3. Stewart JA: Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists. Semin Oncol 15:10–16, 1988

    Google Scholar 

  4. Broome MG, Johnson RK, Wodinsky I: Biochemical and biological characterization of two new antifols, NSC 127755 and TMQ, in comparison with methotrexate. Proc Am Assoc Cancer Res 21:309, 1980 (abstr)

    Google Scholar 

  5. Jackson RC, Leopold WR, Hamelehle KL, Fry DW: Preclinical studies with trimetrexate: a review of conclusions and unanswered questions. Semin Oncol 15:1–7, 1988

    Google Scholar 

  6. Jackson RC, Fry DW, Boritzki TJ: Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 22:187–206, 1986

    Google Scholar 

  7. Kamen BA, Eibl B, Cashmore A, Bertino JR: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline), a nonclassical antifolate, in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 33:1697–1699, 1984

    Google Scholar 

  8. Donehower RC, Graham ML, Thompson GE, Dole GB, Ettinger DS: Phase I and pharmacokinetic study of trimetrexate in patients with advanced cancer. Proc Am Soc Clin Oncol 4:32, 1985 (abstr)

    Google Scholar 

  9. Legha S, Tenney D, Ho DH, Krakoff I: Phase I clinical and pharmacology study of trimetrexate (TMQ). Proc Am Soc Clin Oncol 4:48, 1985 (abstr)

    Google Scholar 

  10. Lin JT, Cashmore AR, Baker M, Dreyer RN, Ernstoff M, Marsh JC, Bertino JR, Whitfield LR, Delap R, Grillo-Lopez A: Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res 47:609–616, 1987

    Google Scholar 

  11. Fanucchi MP, Walsh TD, Fleisher M, Lokos G, Williams L, Cassidy C, Vidal P, Chou T, Niedzwiecki D, Young CW: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303–3308, 1987

    Google Scholar 

  12. Stewart JA, McCormack JJ, Tong W, Delap RJ, Grillo-Lopez AJ: A phase I study of trimetrexate. Proc Am Assoc Cancer Res 26:159, 1985 (abstr)

    Google Scholar 

  13. Jolivet J, Landry L, Pinard MF, Eisenhauer E: Daily bolus × 9 trimetrexate: phase I clinical, pharmacokinetic and pharmacodynamic study. Proc Am Assoc Cancer Res 27:174, 1986 (abstr)

    Google Scholar 

  14. Rosen M, Ohnuma T, Zimet A, Coffey V, Zhang N, Holland JF: Phase I study of trimetrexate (TMTX, TMQ, JB-11) glucuronate in a 5-day infusion schedule. Proc Am Assoc Cancer Res 27:172, 1986 (abstr)

    Google Scholar 

  15. Leiby JM: Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. Semin Oncol 15:27–31, 1988

    Google Scholar 

  16. Asbury RF, Onaan A, Haller D: Eastern Cooperative Oncology Group (ECOG) phase II study of trimetrexate in metastatic gastric cancer. Proc Am Soc Clin Oncol 9:126, 1990 (abstr)

    Google Scholar 

  17. Robert F: Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 15:22–26, 1988

    Google Scholar 

  18. Witte R, Elson P, Khandekar J, Trump D: Trimetrexate (TMQ) in advanced urothelial carcinoma: a phase II evaluation by the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 9:148, 1990 (abstr)

    Google Scholar 

  19. Kris MG, D'Acquisto RW, Gralla RJ, Burke MT, Marks LD, Fanucchi MP, Heelan RT: Phase II trial of trimetrexate in patients with stage III and IV non-small cell lung cancer. Am J Clin Oncol 12:24–26, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Frank V. Fossella, Paul Y. Holoye, Becky Hallinan, Martin N. Raber & Waun Ki Hong

  2. Central Illinois Community Clinical Oncology Program (CCOP), Springfield, Illinois

    Karen Hoelzer

  3. St. Francis Hospital/Natalie Warren Bryant CCOP, Tulsa, Oklahoma

    James A. Young

  4. Twin Tiers CCOP, Binghamton, New York

    Joseph Readling

  5. West Metro-Minneapolis CCOP, St. Louis Park, Minnesota, USA

    Barbara Bowers

Authors
  1. Frank V. Fossella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodger J. Winn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Y. Holoye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Becky Hallinan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin N. Raber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karen Hoelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joseph Readling
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Barbara Bowers
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Waun Ki Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fossella, F.V., Winn, R.J., Holoye, P.Y. et al. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs 10, 331–335 (1992). https://doi.org/10.1007/BF00944191

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00944191

Key words

Search

Navigation